![Scott Young](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Scott A. Young worked as Head-Investor Relations at Invivyd, Inc. from 2023 to 2024.
Mr. Young served as VP-Investor Relations & Corporate Communications at Xilio Therapeutics, Inc. Mr. Young was VP-Corporate Communications & Investor Relations at Flexion Therapeutics, Inc. from 2018 to 2022.
Ehemalige bekannte Positionen von Scott Young
| Unternehmen | Position | Ende |
|---|---|---|
| INVIVYD, INC. | Investor Relations Kontakt | 01.06.2024 |
| FLEXION THERAPEUTICS, INC. | Investor Relations Kontakt | 01.02.2022 |
| XILIO THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
41
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Invivyd, Inc.
 Invivyd, Inc. BiotechnologyHealth Technology Develops antibody-based solutions for infectious diseases | Health Technology |
